GILD - Gilead Sciences, Inc.
| Previous Close | 74.84 |
| Open | 75.16 |
| Bid | 75.40 x 800 |
| Ask | 75.41 x 2200 |
| Day's Range | 74.68 - 75.59 |
| 52 Week Range | 64.27 - 89.54 |
| Volume | 3,159,255 |
| Avg. Volume | 6,639,718 |
| Market Cap | 97.867B |
| Beta | 1.45 |
| PE Ratio (TTM) | 45.10 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.28 (2.93%) |
| Ex-Dividend Date | 2018-09-13 |
| 1y Target Est | N/A |
Market Realist•58 minutes agoWhy Vertex Is Expected to Report Robust EPS Growth in 2018
How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.
Market Realist•2 hours agoVertex Pharmaceuticals Is Expected to See Robust Revenue Growth
In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.
- Zacks•3 hours ago
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
- Motley Fool•5 hours ago
Should Gilead Be Worried About This New Monthly HIV Medication?
The devil is in the undisclosed details.
Reuters•23 hours agoLong-acting injection a shot in the arm for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.
Reuters•yesterdayLong-acting injection a shot in the arm for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.
- Reuters•2 days ago
Congo deploys experimental Ebola treatment as cases rise
GOMA, Democratic Republic of Congo/GENEVA, Aug 14 (Reuters) - D emocratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak. Forty-two people are believed to have died from the haemorrhagic fever in Congo's tenth Ebola outbreak since it was discovered in the 1970s. In all, there have been 66 cases to date, including 39 confirmed and 27 probable, the health ministry said on Tuesday evening, an increase of nine confirmed cases since Monday.
- American City Business Journals•2 days ago
After five months on job, Gilead chief medical officer joins exodus
Dr. Andrew Cheng, appointed in March as chief medical officer of Gilead Sciences Inc., is leaving the company, joining an exodus of top-level executives from the Foster City-based drug developer. Cheng will "pursue another opportunity," Gilead (NASDAQ: GILD) said Tuesday while disclosing two promotions. Dr. Diana Brainard was promoted from vice president of clinical research, to senior vice president of HIV and emerging viral infections, and Gregg Alton, executive vice president of corporate and medical affairs, will become Gilead's first chief patient officer.
- Zacks•3 days ago
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
- Zacks•3 days ago
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
- Zacks•6 days ago
Biotech ETFs in Focus on String of Q2 Earnings Beat
Biotech ETFs draw attention post impressive Q2 results.
- Investopedia•6 days ago
Gilead Sciences Seen Rising 13% on Better Outlook
Gilead Sciences Inc. ( GILD) has risen by more than 18% since the start of May, and it looks likes shares may still be heading even higher. Analysts have been upping their earnings and revenue outlook for the biotech company since it reported blowout second-quarter results at the end of July, and now see the stock rising by nearly 13% based on the average price targets. Analysts have increased their average price on the stock to $87.40 since the company reported results, up from a prior target of $85.84.
- InvestorPlace•6 days ago
You Better Be Careful with Merck Stock, Especially at These Highs
Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.
- Zacks•6 days ago
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Market Realist•7 days agoSangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
- Market Realist•7 days ago
BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
Market Realist•7 days agoHere’s How Exelixis Is Financially Positioned Now
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
- Zacks•7 days ago
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
- Motley Fool•7 days ago
Is Crispr Therapeutics Stock Grossly Overvalued?
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
- Zacks•7 days ago
Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
- Zacks•7 days ago
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
- Market Realist•7 days ago
What Analysts Recommend for Ionis after Q2 2018
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.
- Motley Fool•8 days ago
3 Top Biotech Stocks to Buy in August
It could be the perfect time to add shares in these biotech companies to portfolios ahead of key catalysts.
- American City Business Journals•8 days ago
Backed with $140M, startup launches three-pronged attack on liver diseases
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.
- Zacks•8 days ago
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
